Molecular mechanisms of drug resistance and its reversal in cancer

Critical Reviews in Biotechnology

Volumn 36, Issue 4, 2016, Pages 716-726

  Kartal Yandim, Melis ^a   Adan Gokbulut, Aysun ^a   Baran, Yusuf ^a,b  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^b ABDULLAH GUL UNIVERSITY   (Turkey)

Author keywords

ABC transporters; apoptosis; bioactive sphingolipids; cancer; cell cycle alteration; multidrug resistance

Indexed keywords

CELL DEATH; CHEMOTHERAPY; DRUG THERAPY;

ABC TRANSPORTER; CANCER; CELL CYCLE; MULTIDRUG RESISTANCE; SPHINGOLIPIDS;

DISEASES;

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; GLUCOSYLCERAMIDE; MEMBRANE LIPID; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL COMPARTMENTALIZATION; CLINICAL TRIAL (TOPIC); DRUG ACCUMULATION; DRUG INACTIVATION; DRUG TARGETING; DRUG UPTAKE; HUMAN; MULTIGENE FAMILY; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; CELL CYCLE; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DRUG RESISTANCE, MULTIPLE; HUMANS; MEMBRANE LIPIDS; NEOPLASMS;

EID: 84942314013     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2015.1015957     Document Type: Review

References (119)

1. A.Adan-Gokbulut, M.Kartal-Yandim, G.Iskender, Y.Baran. (2013). Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem, 20, 108–22
2. I.U.Ali, L.M.Schriml, M.Dean. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst, 91, 1922–32
3. S.V.Ambudkar, S.Dey, C.A.Hrycyna,. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 39, 361–98
4. J.P.Annereau, G.Szakács, C.J.Tucker,. (2004). Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol, 66, 1397–405
5. E.R.Balkin, F.Jia, W.H.Miller, M.R.Lewis. (2011). In vitro evaluation of targeted antisense 177Lu radiotherapy. Anticancer Res, 31, 3143–9
6. C.J.Barker, K.Bowler. (1991). Lipid composition of the membranes from cells of two rat tumors and its relationship to tumor thermosensitivity. Radiat Res, 125, 48–55
7. M.Bektas, P.S.Jolly, C.Müller,. (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene, 24, 178–87
8. A.M.Bode, Z.Dong. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer, 4, 793–805
9. K.Bogman, A.K.Peyer, M.Török,. (2001). HMG-CoAreductase inhibitors and P-glycoprotein modulation. Br J Pharmacol, 132, 1183–92
10. P.Borst. (1991). Genetic mechanisms of drug resistance: a review. Acta Oncol, 30, 87–105
11. P.Borst, R.Evers, M.Kool, J.Wijnholds. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 92, 1295–301
12. L.Campos, D.Guyotat, E.Archimbaud,. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473–6
13. M.Castaing, P.Brouant, A.Loiseau,. (2000). Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge. J Pharm Pharmacol, 52, 289–96
14. E.H.Chang, K.F.Pirollo, K.B.Bouker. (2000). Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today, 6, 358–64
15. P.S.Chauhan, B.Bhushan, L.C.Singh,. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol, 92, 44–9
16. C.H.Choi. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int, 30, 1–13
17. M.L.Cuestas, A.Sosnik, V.Mathet. (2011). Poloxamines display a multiple inhibitory activity of ATP-Binding Cassette (ABC) transporters in cancer cell lines. Mol Pharm, 8, 1152–64
18. Daniel C, Bell C, Burton C, et al. (2013). The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochimica et Biophysica Acta, 1832, 606–17
19. M.Das, S.K.Sahoo. (2012). Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One, 7, e32920
20. M.Dean, A.Rzhetsky, R.Alliknets. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 11, 1156–66
21. E.J.Demant, M.Sehested, P.B.Jensen. (1990). A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated transport in multidrug-resistant tumor cells. Biochim Biophys Acta, 1055, 117–25
22. Y.Dönmez, U.Gündüz. (2011). Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother, 65, 85–9
23. N.A.Doudican, S.A.Byron, P.M.Pollock, S.J.Orlow. (2013). XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs, 24, 181–8
24. M.Duvvuri, J.P.Krise. (2005). Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci, 10, 1499–509
25. S.Y.Eid, M.Z.El-Readi, E.E.Eldin,. (2013). Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells. Phytomedicine, 21, 47–61
26. T.Fujita, H.Doihara, K.Washio,. (2006). Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs, 17, 455–62
27. J.W.Gawryluk, J.F.Wang, A.C.Andreazza,. (2011). Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol, 14, 123–30
28. S.R.George, G.Y.Ng, S.P.Lee,. (2003). Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: novel strategy for functional inhibition of membrane proteins in vivo. J Pharmacol Exp Ther, 307, 481–9
29. G.Giaccone, H.M.Pinedo. (1996). Drug resistance. Oncologist, 1, 82–7
30. L.J.Goldstein, H.Galski, A.Fojo,. (1989). Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst, 81, 116–24
31. M.M.Gottesman. (2002). Mechanisms of cancer drug resistance. Ann Rev Med, 53, 615–27
32. V.Gouazé, Y.Y.Liu, C.S.Prickett,. (2005). Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res, 65, 3861–7
33. C.E.Grant, G.Valdimarsson, D.R.Hipfner,. (1994). Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res, 54, 357–61
34. B.L.Grasberger, T.Lu, C.Schubert,. (2005). Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem, 48, 909–12
35. Y.X.Hao, Z.W.He, J.H.Zhu,. (2012). Reversal of multidrug resistance in renal cell carcinoma by short hairpin RNA targeting MDR1 gene. Chin Med J (Engl), 125, 2741–5
36. G.Hapke, M.B.Yin, Y.M.Rustum. (2001). Targeting molecular signals in chk1 pathways as a new approach for overcoming drug resistance. Cancer Metastasis Rev, 20, 109–15
37. R.Honda, H.Tanaka, H.Yasuda. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420, 25–7
38. P.J.Houghton, G.S.Germain, F.C.Harwood,. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res, 64, 2333–7
39. W.Hu, J.J.Kavanagh. (2003). Anticancer therapy targeting the apoptotic pathway. Lancet Oncol, 4, 721–9
40. M.Kartal-Yandim, E.Apohan, Y.Baran. (2013). Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer. Cancer Chemother Pharmacol, 71, 13–20
41. M.Kitazono, H.Okumura, R.Ikeda,. (2001). Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer, 91, 126–31
42. H.K.Koblish, S.Zhao, C.F.Franks,. (2006). Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther, 5, 160–9
43. M.Kool, M.de Haas, G.L.Scheffer,. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res, 57, 3537–47
44. R.Krishna, L.D.Mayer. (2000). Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, 265–83
45. G.D.Kruh, M.G.Belinsky. (2003). The MRP family of drug efflux pumps. Oncogene, 22, 7537–52
46. A.Kumar, S.Kant, S.M.Singh. (2013). Targeting monocarboxylate transporter by α-cyano-4-hydroxycinnamate modulates apoptosis and cisplatin resistance of Colo205 cells: implication of altered cell survival regulation. Apoptosis, 18, 1574–85
47. D.Kunze, K.Erdmann, M.Froehner,. (2012). siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res, 32, 4313–18
48. F.Lamoureux, C.Thomas, C.Crafter,. (2013). Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res, 19, 833–44
49. A.K.Larsen, A.E.Escargueil, A.Skladanowski. (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther, 85, 217–29
50. A.K.Larsen, A.Skladanowski. (1998). Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochem Biophys Acta, 1400, 257–74
51. N.A.Laurie, S.L.Donovan, C.S.Shih,. (2006). Inactivation of the p53 pathway in retinoblastoma. Nature, 444, 61–6
52. M.O.Leach. (1996). Introduction to in vivo MRS of cancer: new perspectives and open problems. Anticancer Res, 16, 1503–14
53. G.D.Leonard, T.Fojo, S.E.Bates. (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411–24
54. J.Li, Z.N.Li, Y.J.Du,. (2009). Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer, 10, 414–21
55. 4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine, 8, 1867–77
56. B.Liedert, V.Materna, D.Schadendorf,. (2003). Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum- DNA adducts and decreased G2-arrest in melano.ma cells resistant to cisplatin. J Invest Dermatol, 121, 172–6
57. S.Lin, K.Hoffmann, Z.Xiao,. (2013). MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int, 13, 1–10
58. M.Liscovitch, Y.Lavie. (2002). Cancer multidrug resistance: a review of recent drug discovery research. IDrugs, 5, 349–55
59. Y.A.Luqmani. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract, 14, 35–48
60. J.Lv, Y.Tian. (2012). Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP. Zhongguo Fei Ai Za Zhi, 15, 501–6
61. B.J.Maurer, L.Melton, C.Billups,. (2000). Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst, 92, 1897–909
62. E.B.Mechetner, I.B.Roninson. (1992). Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA, 89, 5824–8
63. T.E.Merchant, P.Meneses, L.W.Gierke,. (1991). 31P magnetic resonance phospholipid profiles of neoplastic human breast tissues. Br J Cancer, 63, 693–8
64. T.E.Merchant, P.W.de Graaf, B.D.Minsky,. (1993). Esophageal cancer phospholipid characterization by 31P NMR. NMR Biomed, 6, 187–93
65. T.E.Merchant, P.M.Diamantis, G.Lauwers,. (1995). Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles. Cancer, 76, 1715–23
66. M.J.Millward, B.M.Cantwell, N.C.Munro,. (1993). Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer, 67, 1031–5
67. G.J.Mulder, S.Ouwerkerk-Mahadevan. (1997). Modulation of glutathione conjugation in vivo: how to decrease glutathione conjugation in vivo or in intact cellular systems in vitro. Chem Biol Interact, 105, 17–34
68. K.Natarajan, Y.Xie, R.M.T.Baer, D.R.Ross. (2012). Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 83, 1084–103
69. Z.Ni, Z.Bikadi, M.F.Rosenberg, Q.Mao. (2010). Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab, 11, 603–17
70. M.L.O’Brien, K.D.Tew. (1996). Glutathione and related enzymes in multidrug resistance. Eur J Cancer, 32, 967–78
71. B.Ogretmen, Y.A.Hannun. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer, 4, 604–16
72. T.Ozben. (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett, 580, 2903–9
73. K.Palaniyandi, Q.Zhao, X.B.Chang. (2011). Infection of H69AR cells with retroviral particles harboring interfering RNAi significantly reduced the multidrug resistance of these small cell lung cancer cells. Int J Biochem Mol Biol, 2, 155–67
74. Panagiotopoulou V, Richardson G, Jensen OE, Rauch C. (2010). On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space-time” dimension of MDR. Eur Biophys J, 39, 201–11
75. J.Patel, A.K.Mitra. (2001). Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics, 2, 401–15
76. D.Pchejetski, M.Golzio, E.Bonhoure,. (2005). Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res, 65, 11667–75
77. A.Pichler, N.Zelcer, J.L.Prior,. (2005). In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res, 11, 4487–94
78. K.F.Pirollo, K.B.Bouker, E.H.Chang. (2000). Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs, 11, 419–32
79. O.Pluquet, P.Hainaut. (2001). Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett, 174, 1–15
80. S.Ponnusamy, M.Meyers-Needham, C.E.Senkal,. (2010). Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol, 6, 1603–24
81. R.Prajapati, A.T.Sangamwar. (2014). Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: insights from multi-targeted molecular dynamics. Biochim Biophys Acta, 1838, 2882–98
82. A.Prinetti, D.Millimaggi, S.D'Ascenzo,. (2006). Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J, 395, 311–18
83. S.K.Rabindran, D.D.Ross, L.A.Doyle,. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res, 60, 47–50
84. N.S.Radin. (2002). The development of aggressive cancer: a possible role for sphingolipids. Cancer Invest, 20, 779–86
85. Rauch C. (2009). Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data, Eur Biophys J, 38, 829–46
86. Rauch C, Pluen A. (2007). Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density, Eur Biophys J, 36, 121–31
87. J.C.Reed. (1995). Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am, 9, 451–73
88. J.R.Riordan, V.Ling. (1979). Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem, 254, 12701–5
89. R.W.Rooswinkel, B.van de Kooij, M.Verheij, J.Borst. (2012). Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis, 3, e366
90. G.Saito, J.A.Swanson, K.D.Lee. (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev, 55, 199–215
91. A.Sancar, L.A.Lindsey-Boltz, K.Unsal-Kacmaz, S.Linn. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem, 73, 39–85
92. B.Sarkadi, M.Müller. (1997). Search for specific inhibitors of multidrug resistance in cancer. Sem Cancer Biol, 8, 171–82
93. J.C.Schisselbauer, R.Silber, E.Papadopoulos,. (1990). Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res, 50, 3562–68
94. M.A.Shah, G.K.Schwartz. (2001). Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res, 7, 2168–81
95. F.J.Sharom, X.Yu, P.Lu,. (1999). Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol, 58, 571–86
96. E.A.Sherbakova, T.P.Stromskaia, E.I.U.Rybalkina,. (2008). Role of PTEN protein in multidrug resistance of prostate cancer cells. Mol Biol, 42, 487–93
97. Simon S, Roy D, Schindler M. (1994). Intracellular pH and the control of multidrugresistance. Proc Natl Acad Sci USA, 91, 1128–32
98. M.L.Smith, Y.R.Seo. (2002). p53 regulation of DNA excision repair pathways. Mutagenesis, 17, 149–56
99. V.Stambolic, A.Suzuki, J.L.de la Pompa,. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95, 29–39
100. A.A.Stavrovskaya. (2000). Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry, 65, 95–106
101. S.H.Sun, M.Zheng, K.Ding,. (2008). A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther, 7, 845–52
102. G.Szakács, J.K.Paterson, J.A.Ludwig,. (2006). Targeting multidrug resistance in cancer. Nat Rev, 3, 219–34
103. G.Szakács, J.P.Annereau, S.Lababidi,. (2004). Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129–37
104. K.D.Tew. (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res, 54, 4313–20
105. R.J.Veldman, A.Mita, O.Cuvillier,. (2003). The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J, 17, 1144–6
106. B.Visentin, J.A.Vekich, B.J.Sibbald,. (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 9, 225–38
107. N.C.Walworth, R.Bernards. (1996). Rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science, 271, 353–6
108. F.Wang, T.Li, B.Zhang,. (2013). MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun, 434, 688–94
109. W.Wang, F.Rastinejad, W.S.El-Deiry. (2003). Restoring p53-dependent tumor suppression. Cancer Biol Ther, 2, S55–63
110. Z.Wang, Y.Sun. (2010). Targeting p53 for novel anticancer therapy. Transl Oncol, 3, 1–12
111. X.S.Xian, H.Park, M.G.Choi, J.M.Park. (2013). Cannabinoid receptor agonist as an alternative drug in 5-fluorouracil-resistant gastric cancer cells. Anticancer Res, 33, 2541–7
112. Z.Xiao, Z.Chen, A.H.Gunasekera,. (2003). Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem, 278, 21767–73
113. X.U.Yan, Z.H.I.Feng, X.U.Guangming,. (2012). Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416. Biosci Rep, 32, 559–66
114. H.G.Yu, Y.W.Ai, L.L.Yu,. (2008). Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer, 122, 433–43
115. M.Yu, A.Ocana, I.F.Tannock. (2013). Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev, 32, 211–27
116. B.X.Zhao, Y.B.Sun, S.Q.Wang,. (2013). Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NF-κb and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One, 8, e71071
117. Y.Zhao, L.Yu, F.Lou,. (1999). The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia. Zhonghua Nei Ke Za Zhi, 38, 760–3
118. W.Zhu, X.Shan, T.Wang,. (2010). miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, 127, 2520–9
119. W.Zhu, D.Zhu, S.Lu,. (2012). miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol, 29, 384–91